ARCHIVES

Guest Editorial: FDA Must Address Economic Incentives to Resolve Drug Shortages Permanently

This article is from The Cancer Letter archive.

Vol. 38 No. 08 | February 24, 2012

Download PDF Visit The Full Archive

Related Articles

“What Is Good For NCI Is Good For NIH,” Broder Says In Address

January 13, 1995

Emory Executive Objects to Report On Merit review

July 22, 1977

Rev/Vel/Dex Response Rate High In Phase I/II Study

January 25, 2008

DCBD To Fund Diagnostic Clinical Trials By CCOPs, Cooperative Groups

June 30, 1989

CCIRC Loses Policy Making, Protocol Review

September 26, 1975

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

January 25, 2013